ARVINAS, INC. 8-K

What Happened

• Arvinas, Inc. (ARVN) filed an 8-K on June 22, 2026 announcing that Chief Medical Officer Noah Berkowitz, M.D., Ph.D., will depart effective July 3, 2026. Dr. Berkowitz will remain in his role through that date while the company searches for a new CMO.
• The company and Dr. Berkowitz executed a separation agreement on June 22, 2026 that includes a release of claims and post‑employment obligations (confidentiality, cooperation, non‑disparagement, and continued compliance with proprietary agreements).

Key Details

• Departure effective date: July 3, 2026; 8-K filed: June 22, 2026.
• Severance cash pay: continuation of base salary for nine months (subject to non‑revocation and withholding).
• Health coverage: company will pay the portion of health plan premiums for similarly situated active employees for up to nine months.
• Equity treatment: acceleration of vesting for RSUs that, by their terms, would vest on or before May 9, 2027; all other RSUs not accelerated will be forfeited. Acceleration is subject to tax withholding.

Why It Matters

• Leadership transition: losing the CMO is a material executive change for a clinical-stage biotech; the company has begun a search for a replacement and Dr. Berkowitz will remain through July 3 to support continuity.
• Financial and shareholder effects: the separation agreement creates near-term compensation expense (salary continuation, health premiums) and may accelerate equity issuances through RSU vesting, which can have modest short-term accounting and tax consequences.
• Investors should note the specific severance and equity terms disclosed, as they provide clarity on the company’s obligations and management continuity during the transition.